Also referred to as FDA022-BB05, this is an intravenous HER2-targeted monoclonal antibody–drug conjugate (ADC) that binds HER2 on tumor cells, is internalized, and releases an intracellular cytotoxic payload; it may also contribute to HER2 pathway blockade and Fc-mediated effector functions.